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Rigid nanoparticles are solid colloidal particles in size 
less than 1µm, in which the active principle (drug or 
biologically active material) is dissolved, entrapped, 
encapsulated and/or to which the active principle is 
adsorbed or conjugated to the surface.
[1] Some scientists 
restrict the definition to structures with a size range of 1–
100 nm in at least one dimension.
[2] Two major types of 
particulate systems are used in nanomedicines, 1) drug 
molecules dispersed within a dense polymeric/lipid 
matrix, or 2) drug molecules dissolved in a liquid 
core or in a lipid or polymer micelles or vesicles. 
Various colloidal drug carrier systems like liposomes, 
niosomes and microemulsions which are similar to 
polymeric nanoparticles with respect to their shape, size 
and mode of administration, have been employed as an 
alternative to nanoparticles. However, the rigid 
nanoparticles offer additional advantages when compared 
to the other colloidal carriers, such as  easier terminal  
sterilization,  higher stability during  storage and  in-
vivo,  easy dispersion  of lyophilized products for 
administration, protection of the drug against 
degradation due to encapsulation of the drug in the solid 
polymer matrix and modulation of the drug release 




Over the last decade, the biodegradable nanoparticles 
have gained enormous interest for cancer therapy.  The  
polymeric  biodegradable  nanoparticles  have  been  
largely  investigated  for the purpose of controlled and/or 
targeted drug delivery. Biodegradable polymers are 
typically degraded into individual monomers, which 
are metabolized and removed from the body via 
normal metabolic pathways. A number of different 
polymers have been utilized in preparation of 
nanoparticles, but poly(lactide) (PLA) and poly(lactide-
co-glycolide) (PLGA) have been the most popular 
ones.
[6] PLA and PLGA are biocompatible and 
biodegradable and thus, they pose a minimal risk of 
toxic side effects in-vivo. The corona of the polymeric 
nanoparticle acts like a shielding layer to protect the 
encapsulated drug from plasma proteins in-vivo, while 
the targeting ligand facilitates the delivery of 
nanoparticles to the target site. 
 
Nanoparticle size and shape 
 
Since a number of anticancer drugs have a short half-life 
following administration due to their low molecular 
weights, hydrophobicity and degradability
[7]
, it is 
important to  study the effect of particle  size  and  shape  
on  the overall circulation time. Parenteral 
administration of the nanoparticles necessitates their 
size to be as small as possible in order to be able to 
reach the targeted destination especially since the inner 
diameter of the smallest capillaries in human body can be 
as minute as 4 µm.
[8] Furthermore, the nanoparticles 
exhibit the "EPR (Enhanced Permeation and Retention) 
effect" due to the leaky tumor vasculature and poorly 
developed lymph system in tumors.
[9] For the EPR effect 
to occur, it is desirable that nanoparticles be as small as 
possible. The lower limit for the nanoparticle size is set at 
10 nm, to avoid the renal clearance, as the threshold 
diameter for the glomerular filtration is considered to be 
in the range of 8-10nm.
[10] 
 
A number of studies indicate that the nanoparticle 
shape could significantly affect their circulation time.
[11] 
It was shown that the filamentous micelles as long as 
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Nanoparticles have presented a new paradigm in anticancer drug delivery to reduce adverse  effects  and  
improve  therapeutic  outcomes. Nanoparticle surface properties and morphology significantly affect the drug 
delivery to tumors while passive targeting. Conjugations with hyaluronic acid, transferrin and aptamers have 
shown to be effective in active targeting of anticancer drugs to tumor tissues. This review presents an overview of 
some credible techniques of passive and active drug delivery to tumors. 
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18 µM could have a circulation half-life of almost twice 
that of the spherical particles.
[12] It was reported that 
interaction of the nanoparticles with the macrophages 
and contact angle formed could be responsible for 




Nanoparticle surface properties 
Nanoparticles have high surface-to-volume ratios when 
compared to larger particles. Therefore, control of their 
surface properties is crucial to their in-vivo behavior. 
Intravenous administration of polymeric nanoparticles 
or conventional colloidal carriers, leads to their rapid 
removal from the blood circulation by the macrophages 
of the Mononuclear Phagocyte System (MPS), also 
known as Reticuloendothelial System (RES). Within 
seconds of introduction of nanoparticles in the 
bloodstream, plasma proteins called opsonins adsorb 
on the surface of nanoparticles and render them 
'visible' to the macrophages, mainly the Kupffer cells 
or macrophages of the liver, which ultimately 
phagocytize them. Thus, the nanoparticles are removed 
from the bloodstream even before reaching their target site 
of action, making them totally ineffective.
[14,15] There is 
no absolute method to completely inhibit this process of 
opsonization and phagocytosis of nanoparticles, but there 
are ways to slow it down. 
 
Typically, it has been observed that plasma proteins 
are attracted more towards the hydrophobic surface as 
compared for hydrophilic surface. Also, research has 
shown a correlation between surface charge and 
opsonization, with the charged particles having higher 
chances of being opsonized than the neutral ones.
[16]
 A 
widely used method to prevent opsonization is to shield 
the surface of nanoparticles by use of long hydrophilic 
polymer chains that can protect the charged and/or 
hydrophobic nanoparticles from being recognized by 
the plasma proteins. Examples of such polymers are: 
polysaccharides, polyacrylamide, poly(vinyl alcohol), 
poly(vinyl-2- pyrrolidone), PEG and PEG-containing 
copolymers. However, the most popular and commonly 
used polymer are PEG and PEG-containing copolymers 
and the method of decorating a particle surface by 
covalently grafting, entrapping or adsorbing PEG 




Targeting tumor microenvironment 
A major advantage of nanoparticles is their drug targeting 
potential, which has been widely studied in the field of 
cancer therapy.
[18,19,20] Nanoparticles have the ability to 
passively target the chemotherapeutic drug to the tumor 
site by exploiting the tumor blood vessel 
characteristics. This ability to passively targeting of the 
drug could be due to the combination of EPR effect and 
passive diffusion. Additionally, the surface of 
nanoparticles can be conjugated to various targeting 
moieties such as antibodies, aptamers to achieve active 
targeting of the drug. 
 
 
Passive Targeting: To satisfy the increased nutrition 
need of the multiplying tumor cells, there is rapid 
angiogenesis (formation of new blood vessels) in the 
tumor, which results in aberrant tortuosity and 
abnormalities in the basement membrane of newly 
formed tumor blood vessels. Thus, the incomplete tumor 
vasculature demonstrates porous blood vessels with gap 
size ranging from 100-700 nm depending on tumor type, 
allowing the entry of nanoparticles smaller than those 
gaps into the tumor interstitium. Moreover, the tumor 
lymphatic system is also poorly developed, resulting in 
fluid retention in tumors and high interstitial pressure at 
the center of tumors than at the periphery.
[21]
 This causes 
the retention of the nanoparticles that gain entry into the 
tumor interstitium, since these particles are not readily 
extravasated into the lymphatic system. Hence, the 
combined phenomenon of entry into the tumor 
interstitium along with being entrapped in the tumor is 
termed as EPR effect. Therefore, many factors 
influence the EPR effect; 1) regional blood flow to the 
tumor, 2) permeability of the tumor vasculature, 3) 
structural barriers imposed by perivascular tumor cells 




Active Targeting: One of the major challenges in 
cancer chemotherapy today, is the targeted delivery of 
the therapeutic agent to the desired tumor growth site 
avoiding damage to the healthy organs. Active targeting 
involves peripheral conjugation of a targeting moiety, that 
will specifically bind to the tumor cells, to the surface 
of nanoparticles. Thus, the targeted nanoparticles, post 
intravenous administration, can reach the tumor site and 
selectively bind the tumor cells, leading to the reduction 
of chemotherapeutic side effects. 
 
Following are some of the examples of the various 
ways in nanoparticles have been utilized to target drugs 
to cancer cells: 
 
Hyaluronic Acid: Activated hyaluronic acid (HA) 
receptors CD44 and RHAMM are overexpressed on the 
tumor cells
[23] and thus HA-anchored PLGA 
nanoparticulate carriers encapsulating doxorubicin were 
prepared which can bind to HA receptors and get 
internalized into the tumor cells, ultimately resulting in 
targeted drug delivery to the tumor cells. In this case, 
HA is linked to PLGA by a diamine PEG spacer and their 
targeted delivery would lead to increased exogenous 
concentrations of HA assumed to be involved in the 
inhibition of tumor metastasis. Thus, the HA-PEG-
PLGA nanoparticles were able to deliver high 
concentrations of doxorubicin to the tumor as compared 
with monomethoxy (polyethylene glycol) (mPEG)-PLGA 
which reduced the tumor volume significantly after IV 




Transferrin: Transferrin receptors (TfR) are 
overexpressed in tumor tissues as compared to the 
normal tissues and thus transferrin, a glycoprotein, can 
be utilized as a ligand for drug targeting to tumor.
[25,26]
 




Conjugation of the amine group of Transferrin to the 
hydroxyl group of PLGA nanoparticles encapsulating 
the chemotherapeutic drug Paclitaxel, via the epoxy 
linker facilitates the transcytosis of the carrier system.
[27]
 
Transferrin has also been shown to overcome multi-drug 
resistance due to P-gp
[28,29] which is overexpressed on 
the tumor cell membrane and known to limit the 
intracellular uptake of anticancer drugs thereby 
decreasing their therapeutic efficacy.
[30]
 Thus, delivery 
of Transferrin conjugated paclitaxel loaded 
nanoparticles causes high and sustained intracellular 
drug levels as well as increase the antiproliferative action 
of the drug as compared to that of the unconjugated 
nanoparticles. 
 
Aptamers: Farokhzad and Langer labs have successfully 
shown the delivery of aptamer conjugated polymeric 
nanoparticles to tumor cells for imaging as well as drug 
delivery purposes. They covalently linked a 5' amine 
terminated A10 RNA aptamer that binds to PSMA 
over expressed on the prostate tumor cells, to PLGA-
PEG nanoparticles showing desirable size and drug 
loading. The conjugation was carried out using the 
carbodiimide chemistry in which the terminal carboxyl 
group of the polymer reacts with the 5' amine group 
of aptamer forming an amide linkage. These 
functionalized nanoparticles displayed active binding 
and cell uptake in-vitro as well as enhanced nanoparticle 
delivery to the prostate tumors in-vivo as compared to the 
equivalent non-functionalized nanoparticles. As 
reported in their study, the drug loaded nanoparticle-
aptamer conjugate showed about 20% decrease in cell 
viability as compared to the drug nanoparticles alone. 
Whereas, the in vivo results obtained in mice, 
supported the in vitro results by confirming the 
superiority of nanoparticle-aptamer conjugate in 
targeting the tumor site.
[31] Another study from the 
Farokhzad and Langer labs, have shown the use of PSMA 
targeted aptamer-nanoparticle conjugate to also deliver 




Nanoparticles, owing to their characteristics and 
advantages, are being used extensively to study their 
potential in delivering various drugs/proteins. Their 
ability to show passive targeting as well as active 
targeting make them an attractive drug delivery approach 
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